nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—PLK1—skin of body—atopic dermatitis	0.00876	0.0453	CbGeAlD
Ruxolitinib—JAK1—neck—atopic dermatitis	0.00867	0.0448	CbGeAlD
Ruxolitinib—GRK7—head—atopic dermatitis	0.00841	0.0434	CbGeAlD
Ruxolitinib—Tuberculosis—Dexamethasone—atopic dermatitis	0.00785	0.0331	CcSEcCtD
Ruxolitinib—Tuberculosis—Betamethasone—atopic dermatitis	0.00785	0.0331	CcSEcCtD
Ruxolitinib—ANKK1—head—atopic dermatitis	0.00769	0.0397	CbGeAlD
Ruxolitinib—CYP3A4—Pimecrolimus—atopic dermatitis	0.00718	0.258	CbGbCtD
Ruxolitinib—Tuberculosis—Prednisone—atopic dermatitis	0.00683	0.0288	CcSEcCtD
Ruxolitinib—BMP2K—neck—atopic dermatitis	0.00649	0.0335	CbGeAlD
Ruxolitinib—PRKG2—head—atopic dermatitis	0.00637	0.0329	CbGeAlD
Ruxolitinib—GRK1—head—atopic dermatitis	0.00608	0.0314	CbGeAlD
Ruxolitinib—PRKCE—head—atopic dermatitis	0.00595	0.0307	CbGeAlD
Ruxolitinib—PLK1—head—atopic dermatitis	0.00572	0.0295	CbGeAlD
Ruxolitinib—RPS6KA6—head—atopic dermatitis	0.00572	0.0295	CbGeAlD
Ruxolitinib—MAST1—head—atopic dermatitis	0.00572	0.0295	CbGeAlD
Ruxolitinib—JAK1—skin of body—atopic dermatitis	0.00561	0.029	CbGeAlD
Ruxolitinib—RET—neck—atopic dermatitis	0.00552	0.0285	CbGeAlD
Ruxolitinib—DCLK3—head—atopic dermatitis	0.00542	0.028	CbGeAlD
Ruxolitinib—PLK1—Tacrolimus—Pimecrolimus—atopic dermatitis	0.0051	0.368	CbGdCrCtD
Ruxolitinib—PLK3—head—atopic dermatitis	0.00477	0.0246	CbGeAlD
Ruxolitinib—BMPR2—skin of body—atopic dermatitis	0.00469	0.0242	CbGeAlD
Ruxolitinib—LTK—head—atopic dermatitis	0.00461	0.0238	CbGeAlD
Ruxolitinib—CAMK1—head—atopic dermatitis	0.00446	0.0231	CbGeAlD
Ruxolitinib—MARK2—head—atopic dermatitis	0.00433	0.0224	CbGeAlD
Ruxolitinib—CYP3A4—Tacrolimus—atopic dermatitis	0.00427	0.153	CbGbCtD
Ruxolitinib—Infestation NOS—Desonide—atopic dermatitis	0.00391	0.0165	CcSEcCtD
Ruxolitinib—Infestation—Desonide—atopic dermatitis	0.00391	0.0165	CcSEcCtD
Ruxolitinib—Contusion—Mometasone—atopic dermatitis	0.00387	0.0163	CcSEcCtD
Ruxolitinib—TYK2—skin of body—atopic dermatitis	0.00371	0.0192	CbGeAlD
Ruxolitinib—JAK3—head—atopic dermatitis	0.00368	0.019	CbGeAlD
Ruxolitinib—DCLK1—head—atopic dermatitis	0.00366	0.0189	CbGeAlD
Ruxolitinib—JAK1—head—atopic dermatitis	0.00366	0.0189	CbGeAlD
Ruxolitinib—CAMK1D—head—atopic dermatitis	0.00357	0.0185	CbGeAlD
Ruxolitinib—Herpes zoster—Tacrolimus—atopic dermatitis	0.00357	0.0151	CcSEcCtD
Ruxolitinib—PHKG2—head—atopic dermatitis	0.00355	0.0184	CbGeAlD
Ruxolitinib—STK16—head—atopic dermatitis	0.00344	0.0177	CbGeAlD
Ruxolitinib—HIPK2—head—atopic dermatitis	0.00342	0.0177	CbGeAlD
Ruxolitinib—JAK2—skin of body—atopic dermatitis	0.00337	0.0174	CbGeAlD
Ruxolitinib—MAP3K19—head—atopic dermatitis	0.00335	0.0173	CbGeAlD
Ruxolitinib—DAPK3—head—atopic dermatitis	0.00328	0.017	CbGeAlD
Ruxolitinib—MAP3K3—skin of body—atopic dermatitis	0.00325	0.0168	CbGeAlD
Ruxolitinib—CLK2—head—atopic dermatitis	0.00325	0.0168	CbGeAlD
Ruxolitinib—ROCK1—head—atopic dermatitis	0.00315	0.0163	CbGeAlD
Ruxolitinib—CYP3A4—Loratadine—atopic dermatitis	0.00312	0.112	CbGbCtD
Ruxolitinib—DYRK1A—head—atopic dermatitis	0.00307	0.0159	CbGeAlD
Ruxolitinib—BMPR2—head—atopic dermatitis	0.00306	0.0158	CbGeAlD
Ruxolitinib—CYP3A4—Methylprednisolone—atopic dermatitis	0.00286	0.103	CbGbCtD
Ruxolitinib—Hypercholesterolaemia—Tacrolimus—atopic dermatitis	0.00284	0.012	CcSEcCtD
Ruxolitinib—Infestation—Pimecrolimus—atopic dermatitis	0.00276	0.0117	CcSEcCtD
Ruxolitinib—Infestation NOS—Pimecrolimus—atopic dermatitis	0.00276	0.0117	CcSEcCtD
Ruxolitinib—BMP2K—head—atopic dermatitis	0.00274	0.0142	CbGeAlD
Ruxolitinib—CAMK2G—head—atopic dermatitis	0.00274	0.0142	CbGeAlD
Ruxolitinib—LRRK2—head—atopic dermatitis	0.00272	0.014	CbGeAlD
Ruxolitinib—Epistaxis—Pimecrolimus—atopic dermatitis	0.00261	0.011	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Desonide—atopic dermatitis	0.00259	0.0109	CcSEcCtD
Ruxolitinib—MAP3K2—head—atopic dermatitis	0.00249	0.0129	CbGeAlD
Ruxolitinib—Infection—Desonide—atopic dermatitis	0.00248	0.0105	CcSEcCtD
Ruxolitinib—Nervous system disorder—Desonide—atopic dermatitis	0.00245	0.0103	CcSEcCtD
Ruxolitinib—Skin disorder—Desonide—atopic dermatitis	0.00242	0.0102	CcSEcCtD
Ruxolitinib—TYK2—head—atopic dermatitis	0.00242	0.0125	CbGeAlD
Ruxolitinib—MKNK2—head—atopic dermatitis	0.00239	0.0123	CbGeAlD
Ruxolitinib—RET—head—atopic dermatitis	0.00233	0.012	CbGeAlD
Ruxolitinib—JAK2—head—atopic dermatitis	0.0022	0.0114	CbGeAlD
Ruxolitinib—CYP3A4—Triamcinolone—atopic dermatitis	0.00216	0.0778	CbGbCtD
Ruxolitinib—Malnutrition—Pimecrolimus—atopic dermatitis	0.00216	0.00911	CcSEcCtD
Ruxolitinib—MAP3K3—head—atopic dermatitis	0.00212	0.011	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Fluocinonide—atopic dermatitis	0.0021	0.00883	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Loratadine—atopic dermatitis	0.00208	0.00878	CcSEcCtD
Ruxolitinib—Epistaxis—Loratadine—atopic dermatitis	0.00208	0.00876	CcSEcCtD
Ruxolitinib—Infection—Fluocinonide—atopic dermatitis	0.00201	0.00847	CcSEcCtD
Ruxolitinib—Nervous system disorder—Fluocinonide—atopic dermatitis	0.00198	0.00836	CcSEcCtD
Ruxolitinib—Infestation—Fluocinolone Acetonide—atopic dermatitis	0.00198	0.00834	CcSEcCtD
Ruxolitinib—Infestation NOS—Fluocinolone Acetonide—atopic dermatitis	0.00198	0.00834	CcSEcCtD
Ruxolitinib—Skin disorder—Fluocinonide—atopic dermatitis	0.00196	0.00828	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Tacrolimus—atopic dermatitis	0.00195	0.00823	CcSEcCtD
Ruxolitinib—TAOK3—head—atopic dermatitis	0.00193	0.01	CbGeAlD
Ruxolitinib—Contusion—Hydrocortisone—atopic dermatitis	0.00192	0.00811	CcSEcCtD
Ruxolitinib—CYP3A4—Betamethasone—atopic dermatitis	0.00186	0.0667	CbGbCtD
Ruxolitinib—Urinary tract infection—Mometasone—atopic dermatitis	0.00184	0.00775	CcSEcCtD
Ruxolitinib—CYP3A4—Prednisolone—atopic dermatitis	0.00183	0.0658	CbGbCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Pimecrolimus—atopic dermatitis	0.00183	0.0077	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Dimenhydrinate—atopic dermatitis	0.00179	0.00753	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Diphenhydramine—atopic dermatitis	0.00179	0.00753	CcSEcCtD
Ruxolitinib—Epistaxis—Mometasone—atopic dermatitis	0.00178	0.00752	CcSEcCtD
Ruxolitinib—Pruritus—Desonide—atopic dermatitis	0.00177	0.00745	CcSEcCtD
Ruxolitinib—Infection—Pimecrolimus—atopic dermatitis	0.00175	0.00739	CcSEcCtD
Ruxolitinib—CYP3A4—Hydrocortisone—atopic dermatitis	0.00174	0.0624	CbGbCtD
Ruxolitinib—CYP3A4—Prednisone—atopic dermatitis	0.00173	0.0622	CbGbCtD
Ruxolitinib—Nervous system disorder—Pimecrolimus—atopic dermatitis	0.00173	0.00729	CcSEcCtD
Ruxolitinib—Skin disorder—Pimecrolimus—atopic dermatitis	0.00171	0.00722	CcSEcCtD
Ruxolitinib—Contusion—Betamethasone—atopic dermatitis	0.00164	0.00693	CcSEcCtD
Ruxolitinib—Contusion—Dexamethasone—atopic dermatitis	0.00164	0.00693	CcSEcCtD
Ruxolitinib—Pancytopenia—Tacrolimus—atopic dermatitis	0.0016	0.00675	CcSEcCtD
Ruxolitinib—Neutropenia—Tacrolimus—atopic dermatitis	0.00158	0.00665	CcSEcCtD
Ruxolitinib—Fatigue—Dimenhydrinate—atopic dermatitis	0.00157	0.00663	CcSEcCtD
Ruxolitinib—Fatigue—Diphenhydramine—atopic dermatitis	0.00157	0.00663	CcSEcCtD
Ruxolitinib—Headache—Desonide—atopic dermatitis	0.00156	0.00659	CcSEcCtD
Ruxolitinib—Malnutrition—Fluocinolone Acetonide—atopic dermatitis	0.00155	0.00652	CcSEcCtD
Ruxolitinib—Weight increased—Tacrolimus—atopic dermatitis	0.00154	0.00647	CcSEcCtD
Ruxolitinib—Weight decreased—Tacrolimus—atopic dermatitis	0.00153	0.00643	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Pimecrolimus—atopic dermatitis	0.00152	0.00642	CcSEcCtD
Ruxolitinib—Infestation NOS—Tacrolimus—atopic dermatitis	0.0015	0.00634	CcSEcCtD
Ruxolitinib—Infestation—Tacrolimus—atopic dermatitis	0.0015	0.00634	CcSEcCtD
Ruxolitinib—Urinary tract infection—Tacrolimus—atopic dermatitis	0.00146	0.00616	CcSEcCtD
Ruxolitinib—PLK1—Everolimus—Pimecrolimus—atopic dermatitis	0.00146	0.105	CbGdCrCtD
Ruxolitinib—PLK1—Temsirolimus—Tacrolimus—atopic dermatitis	0.00146	0.105	CbGdCrCtD
Ruxolitinib—PLK1—Sirolimus—Pimecrolimus—atopic dermatitis	0.00146	0.105	CbGdCrCtD
Ruxolitinib—PLK1—Temsirolimus—Pimecrolimus—atopic dermatitis	0.00146	0.105	CbGdCrCtD
Ruxolitinib—PLK1—Everolimus—Tacrolimus—atopic dermatitis	0.00146	0.105	CbGdCrCtD
Ruxolitinib—PLK1—Sirolimus—Tacrolimus—atopic dermatitis	0.00146	0.105	CbGdCrCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Loratadine—atopic dermatitis	0.00145	0.00613	CcSEcCtD
Ruxolitinib—Haematuria—Tacrolimus—atopic dermatitis	0.00143	0.00605	CcSEcCtD
Ruxolitinib—Pruritus—Fluocinonide—atopic dermatitis	0.00143	0.00603	CcSEcCtD
Ruxolitinib—Contusion—Prednisone—atopic dermatitis	0.00143	0.00603	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Tacrolimus—atopic dermatitis	0.00142	0.006	CcSEcCtD
Ruxolitinib—Epistaxis—Tacrolimus—atopic dermatitis	0.00142	0.00598	CcSEcCtD
Ruxolitinib—Body temperature increased—Pimecrolimus—atopic dermatitis	0.00139	0.00588	CcSEcCtD
Ruxolitinib—Nervous system disorder—Loratadine—atopic dermatitis	0.00138	0.00581	CcSEcCtD
Ruxolitinib—Skin disorder—Loratadine—atopic dermatitis	0.00136	0.00575	CcSEcCtD
Ruxolitinib—Haemoglobin—Tacrolimus—atopic dermatitis	0.00136	0.00572	CcSEcCtD
Ruxolitinib—Haemorrhage—Tacrolimus—atopic dermatitis	0.00135	0.00569	CcSEcCtD
Ruxolitinib—Dizziness—Fluocinonide—atopic dermatitis	0.00134	0.00564	CcSEcCtD
Ruxolitinib—Hypercholesterolaemia—Prednisone—atopic dermatitis	0.00132	0.00556	CcSEcCtD
Ruxolitinib—Asthenia—Dimenhydrinate—atopic dermatitis	0.00131	0.00552	CcSEcCtD
Ruxolitinib—Asthenia—Diphenhydramine—atopic dermatitis	0.00131	0.00552	CcSEcCtD
Ruxolitinib—Headache—Fluocinonide—atopic dermatitis	0.00127	0.00534	CcSEcCtD
Ruxolitinib—Infection—Fluocinolone Acetonide—atopic dermatitis	0.00125	0.00529	CcSEcCtD
Ruxolitinib—Pruritus—Pimecrolimus—atopic dermatitis	0.00125	0.00526	CcSEcCtD
Ruxolitinib—Nervous system disorder—Fluocinolone Acetonide—atopic dermatitis	0.00124	0.00522	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Loratadine—atopic dermatitis	0.00121	0.00511	CcSEcCtD
Ruxolitinib—Fatigue—Loratadine—atopic dermatitis	0.00121	0.00511	CcSEcCtD
Ruxolitinib—Dizziness—Dimenhydrinate—atopic dermatitis	0.00121	0.00508	CcSEcCtD
Ruxolitinib—Dizziness—Diphenhydramine—atopic dermatitis	0.00121	0.00508	CcSEcCtD
Ruxolitinib—Infection—Mometasone—atopic dermatitis	0.0012	0.00505	CcSEcCtD
Ruxolitinib—Malnutrition—Tacrolimus—atopic dermatitis	0.00118	0.00496	CcSEcCtD
Ruxolitinib—Flatulence—Tacrolimus—atopic dermatitis	0.00116	0.00488	CcSEcCtD
Ruxolitinib—Headache—Diphenhydramine—atopic dermatitis	0.00114	0.00482	CcSEcCtD
Ruxolitinib—Headache—Dimenhydrinate—atopic dermatitis	0.00114	0.00482	CcSEcCtD
Ruxolitinib—Body temperature increased—Loratadine—atopic dermatitis	0.00111	0.00468	CcSEcCtD
Ruxolitinib—Headache—Pimecrolimus—atopic dermatitis	0.0011	0.00466	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Fluocinolone Acetonide—atopic dermatitis	0.00109	0.00459	CcSEcCtD
Ruxolitinib—Anaemia—Tacrolimus—atopic dermatitis	0.00109	0.00458	CcSEcCtD
Ruxolitinib—CYP3A4—Dexamethasone—atopic dermatitis	0.00108	0.0388	CbGbCtD
Ruxolitinib—Alanine aminotransferase increased—Hydrocortisone—atopic dermatitis	0.00107	0.00453	CcSEcCtD
Ruxolitinib—Fatigue—Mometasone—atopic dermatitis	0.00104	0.00438	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Methylprednisolone—atopic dermatitis	0.00101	0.00425	CcSEcCtD
Ruxolitinib—Asthenia—Loratadine—atopic dermatitis	0.00101	0.00425	CcSEcCtD
Ruxolitinib—Body temperature increased—Fluocinolone Acetonide—atopic dermatitis	0.000998	0.00421	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Tacrolimus—atopic dermatitis	0.000994	0.00419	CcSEcCtD
Ruxolitinib—Weight increased—Prednisolone—atopic dermatitis	0.000981	0.00413	CcSEcCtD
Ruxolitinib—Weight increased—Hydrocortisone—atopic dermatitis	0.000958	0.00404	CcSEcCtD
Ruxolitinib—Infection—Tacrolimus—atopic dermatitis	0.000953	0.00402	CcSEcCtD
Ruxolitinib—Body temperature increased—Mometasone—atopic dermatitis	0.000953	0.00402	CcSEcCtD
Ruxolitinib—Weight decreased—Hydrocortisone—atopic dermatitis	0.000952	0.00401	CcSEcCtD
Ruxolitinib—Nervous system disorder—Tacrolimus—atopic dermatitis	0.000941	0.00397	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Tacrolimus—atopic dermatitis	0.000939	0.00396	CcSEcCtD
Ruxolitinib—Infestation NOS—Hydrocortisone—atopic dermatitis	0.000938	0.00396	CcSEcCtD
Ruxolitinib—Infestation—Hydrocortisone—atopic dermatitis	0.000938	0.00396	CcSEcCtD
Ruxolitinib—Skin disorder—Tacrolimus—atopic dermatitis	0.000932	0.00393	CcSEcCtD
Ruxolitinib—Dizziness—Loratadine—atopic dermatitis	0.000929	0.00392	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Prednisone—atopic dermatitis	0.000906	0.00382	CcSEcCtD
Ruxolitinib—Weight increased—Triamcinolone—atopic dermatitis	0.000902	0.0038	CcSEcCtD
Ruxolitinib—Weight increased—Methylprednisolone—atopic dermatitis	0.0009	0.00379	CcSEcCtD
Ruxolitinib—Pruritus—Fluocinolone Acetonide—atopic dermatitis	0.000893	0.00377	CcSEcCtD
Ruxolitinib—Infestation NOS—Methylprednisolone—atopic dermatitis	0.000882	0.00372	CcSEcCtD
Ruxolitinib—Infestation—Methylprednisolone—atopic dermatitis	0.000882	0.00372	CcSEcCtD
Ruxolitinib—Headache—Loratadine—atopic dermatitis	0.00088	0.00371	CcSEcCtD
Ruxolitinib—Haemoglobin—Prednisolone—atopic dermatitis	0.000867	0.00365	CcSEcCtD
Ruxolitinib—Asthenia—Mometasone—atopic dermatitis	0.000865	0.00365	CcSEcCtD
Ruxolitinib—Haemorrhage—Prednisolone—atopic dermatitis	0.000862	0.00364	CcSEcCtD
Ruxolitinib—Pruritus—Mometasone—atopic dermatitis	0.000853	0.0036	CcSEcCtD
Ruxolitinib—Haemoglobin—Hydrocortisone—atopic dermatitis	0.000847	0.00357	CcSEcCtD
Ruxolitinib—Haemorrhage—Hydrocortisone—atopic dermatitis	0.000842	0.00355	CcSEcCtD
Ruxolitinib—Dizziness—Fluocinolone Acetonide—atopic dermatitis	0.000835	0.00352	CcSEcCtD
Ruxolitinib—Epistaxis—Triamcinolone—atopic dermatitis	0.000833	0.00351	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Tacrolimus—atopic dermatitis	0.000828	0.00349	CcSEcCtD
Ruxolitinib—Fatigue—Tacrolimus—atopic dermatitis	0.000827	0.00349	CcSEcCtD
Ruxolitinib—Weight increased—Dexamethasone—atopic dermatitis	0.000818	0.00345	CcSEcCtD
Ruxolitinib—Weight increased—Betamethasone—atopic dermatitis	0.000818	0.00345	CcSEcCtD
Ruxolitinib—Weight decreased—Betamethasone—atopic dermatitis	0.000813	0.00343	CcSEcCtD
Ruxolitinib—Weight decreased—Dexamethasone—atopic dermatitis	0.000813	0.00343	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Prednisone—atopic dermatitis	0.000799	0.00337	CcSEcCtD
Ruxolitinib—Haemoglobin—Triamcinolone—atopic dermatitis	0.000797	0.00336	CcSEcCtD
Ruxolitinib—Haemoglobin—Methylprednisolone—atopic dermatitis	0.000795	0.00335	CcSEcCtD
Ruxolitinib—Haemorrhage—Triamcinolone—atopic dermatitis	0.000793	0.00334	CcSEcCtD
Ruxolitinib—Haemorrhage—Methylprednisolone—atopic dermatitis	0.000791	0.00334	CcSEcCtD
Ruxolitinib—Headache—Fluocinolone Acetonide—atopic dermatitis	0.000791	0.00333	CcSEcCtD
Ruxolitinib—Body temperature increased—Tacrolimus—atopic dermatitis	0.000758	0.0032	CcSEcCtD
Ruxolitinib—Headache—Mometasone—atopic dermatitis	0.000755	0.00318	CcSEcCtD
Ruxolitinib—Malnutrition—Hydrocortisone—atopic dermatitis	0.000733	0.00309	CcSEcCtD
Ruxolitinib—Neutropenia—Prednisone—atopic dermatitis	0.000732	0.00309	CcSEcCtD
Ruxolitinib—Haemoglobin—Betamethasone—atopic dermatitis	0.000723	0.00305	CcSEcCtD
Ruxolitinib—Haemoglobin—Dexamethasone—atopic dermatitis	0.000723	0.00305	CcSEcCtD
Ruxolitinib—Haemorrhage—Betamethasone—atopic dermatitis	0.00072	0.00303	CcSEcCtD
Ruxolitinib—Haemorrhage—Dexamethasone—atopic dermatitis	0.00072	0.00303	CcSEcCtD
Ruxolitinib—Weight increased—Prednisone—atopic dermatitis	0.000713	0.003	CcSEcCtD
Ruxolitinib—Weight decreased—Prednisone—atopic dermatitis	0.000708	0.00299	CcSEcCtD
Ruxolitinib—Malnutrition—Methylprednisolone—atopic dermatitis	0.000689	0.0029	CcSEcCtD
Ruxolitinib—Asthenia—Tacrolimus—atopic dermatitis	0.000688	0.0029	CcSEcCtD
Ruxolitinib—Pruritus—Tacrolimus—atopic dermatitis	0.000679	0.00286	CcSEcCtD
Ruxolitinib—Dizziness—Tacrolimus—atopic dermatitis	0.000634	0.00267	CcSEcCtD
Ruxolitinib—Haemoglobin—Prednisone—atopic dermatitis	0.00063	0.00266	CcSEcCtD
Ruxolitinib—Haemorrhage—Prednisone—atopic dermatitis	0.000627	0.00264	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—atopic dermatitis	0.00062	0.00261	CcSEcCtD
Ruxolitinib—Headache—Tacrolimus—atopic dermatitis	0.000601	0.00253	CcSEcCtD
Ruxolitinib—Infection—Hydrocortisone—atopic dermatitis	0.000595	0.00251	CcSEcCtD
Ruxolitinib—Nervous system disorder—Hydrocortisone—atopic dermatitis	0.000587	0.00247	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—atopic dermatitis	0.000582	0.00246	CcSEcCtD
Ruxolitinib—Skin disorder—Hydrocortisone—atopic dermatitis	0.000581	0.00245	CcSEcCtD
Ruxolitinib—Infection—Triamcinolone—atopic dermatitis	0.00056	0.00236	CcSEcCtD
Ruxolitinib—Infection—Methylprednisolone—atopic dermatitis	0.000559	0.00236	CcSEcCtD
Ruxolitinib—Nervous system disorder—Methylprednisolone—atopic dermatitis	0.000551	0.00232	CcSEcCtD
Ruxolitinib—Skin disorder—Methylprednisolone—atopic dermatitis	0.000546	0.0023	CcSEcCtD
Ruxolitinib—Malnutrition—Prednisone—atopic dermatitis	0.000546	0.0023	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Hydrocortisone—atopic dermatitis	0.000517	0.00218	CcSEcCtD
Ruxolitinib—Fatigue—Hydrocortisone—atopic dermatitis	0.000516	0.00218	CcSEcCtD
Ruxolitinib—Infection—Dexamethasone—atopic dermatitis	0.000508	0.00214	CcSEcCtD
Ruxolitinib—Infection—Betamethasone—atopic dermatitis	0.000508	0.00214	CcSEcCtD
Ruxolitinib—Anaemia—Prednisone—atopic dermatitis	0.000504	0.00213	CcSEcCtD
Ruxolitinib—Nervous system disorder—Dexamethasone—atopic dermatitis	0.000501	0.00211	CcSEcCtD
Ruxolitinib—Nervous system disorder—Betamethasone—atopic dermatitis	0.000501	0.00211	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Betamethasone—atopic dermatitis	0.000501	0.00211	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Dexamethasone—atopic dermatitis	0.000501	0.00211	CcSEcCtD
Ruxolitinib—Fatigue—Triamcinolone—atopic dermatitis	0.000486	0.00205	CcSEcCtD
Ruxolitinib—Fatigue—Methylprednisolone—atopic dermatitis	0.000485	0.00204	CcSEcCtD
Ruxolitinib—Body temperature increased—Hydrocortisone—atopic dermatitis	0.000473	0.00199	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—atopic dermatitis	0.000461	0.00194	CcSEcCtD
Ruxolitinib—Body temperature increased—Triamcinolone—atopic dermatitis	0.000445	0.00188	CcSEcCtD
Ruxolitinib—Infection—Prednisone—atopic dermatitis	0.000442	0.00187	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Betamethasone—atopic dermatitis	0.000441	0.00186	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Dexamethasone—atopic dermatitis	0.000441	0.00186	CcSEcCtD
Ruxolitinib—Fatigue—Dexamethasone—atopic dermatitis	0.000441	0.00186	CcSEcCtD
Ruxolitinib—Fatigue—Betamethasone—atopic dermatitis	0.000441	0.00186	CcSEcCtD
Ruxolitinib—Nervous system disorder—Prednisone—atopic dermatitis	0.000437	0.00184	CcSEcCtD
Ruxolitinib—Skin disorder—Prednisone—atopic dermatitis	0.000432	0.00182	CcSEcCtD
Ruxolitinib—Asthenia—Hydrocortisone—atopic dermatitis	0.000429	0.00181	CcSEcCtD
Ruxolitinib—Pruritus—Hydrocortisone—atopic dermatitis	0.000423	0.00179	CcSEcCtD
Ruxolitinib—Dizziness—Prednisolone—atopic dermatitis	0.000405	0.00171	CcSEcCtD
Ruxolitinib—Asthenia—Triamcinolone—atopic dermatitis	0.000404	0.0017	CcSEcCtD
Ruxolitinib—Body temperature increased—Dexamethasone—atopic dermatitis	0.000404	0.0017	CcSEcCtD
Ruxolitinib—Body temperature increased—Betamethasone—atopic dermatitis	0.000404	0.0017	CcSEcCtD
Ruxolitinib—Asthenia—Methylprednisolone—atopic dermatitis	0.000403	0.0017	CcSEcCtD
Ruxolitinib—Pruritus—Triamcinolone—atopic dermatitis	0.000399	0.00168	CcSEcCtD
Ruxolitinib—Pruritus—Methylprednisolone—atopic dermatitis	0.000398	0.00168	CcSEcCtD
Ruxolitinib—Dizziness—Hydrocortisone—atopic dermatitis	0.000396	0.00167	CcSEcCtD
Ruxolitinib—Fatigue—Prednisone—atopic dermatitis	0.000384	0.00162	CcSEcCtD
Ruxolitinib—Headache—Prednisolone—atopic dermatitis	0.000384	0.00162	CcSEcCtD
Ruxolitinib—Headache—Hydrocortisone—atopic dermatitis	0.000375	0.00158	CcSEcCtD
Ruxolitinib—Dizziness—Triamcinolone—atopic dermatitis	0.000373	0.00157	CcSEcCtD
Ruxolitinib—Dizziness—Methylprednisolone—atopic dermatitis	0.000372	0.00157	CcSEcCtD
Ruxolitinib—Asthenia—Dexamethasone—atopic dermatitis	0.000367	0.00155	CcSEcCtD
Ruxolitinib—Asthenia—Betamethasone—atopic dermatitis	0.000367	0.00155	CcSEcCtD
Ruxolitinib—Pruritus—Dexamethasone—atopic dermatitis	0.000362	0.00153	CcSEcCtD
Ruxolitinib—Pruritus—Betamethasone—atopic dermatitis	0.000362	0.00153	CcSEcCtD
Ruxolitinib—Headache—Triamcinolone—atopic dermatitis	0.000353	0.00149	CcSEcCtD
Ruxolitinib—Headache—Methylprednisolone—atopic dermatitis	0.000352	0.00149	CcSEcCtD
Ruxolitinib—Body temperature increased—Prednisone—atopic dermatitis	0.000352	0.00148	CcSEcCtD
Ruxolitinib—Dizziness—Dexamethasone—atopic dermatitis	0.000338	0.00143	CcSEcCtD
Ruxolitinib—Dizziness—Betamethasone—atopic dermatitis	0.000338	0.00143	CcSEcCtD
Ruxolitinib—Headache—Dexamethasone—atopic dermatitis	0.00032	0.00135	CcSEcCtD
Ruxolitinib—Headache—Betamethasone—atopic dermatitis	0.00032	0.00135	CcSEcCtD
Ruxolitinib—Asthenia—Prednisone—atopic dermatitis	0.000319	0.00135	CcSEcCtD
Ruxolitinib—Pruritus—Prednisone—atopic dermatitis	0.000315	0.00133	CcSEcCtD
Ruxolitinib—Dizziness—Prednisone—atopic dermatitis	0.000294	0.00124	CcSEcCtD
Ruxolitinib—Headache—Prednisone—atopic dermatitis	0.000279	0.00118	CcSEcCtD
Ruxolitinib—JAK2—DAP12 interactions—IL6—atopic dermatitis	3.81e-05	7.23e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Fc epsilon receptor (FCERI) signaling—IL6—atopic dermatitis	3.81e-05	7.23e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CCL5—atopic dermatitis	3.79e-05	7.18e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CXCL10—atopic dermatitis	3.79e-05	7.18e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by EGFR—IL6—atopic dermatitis	3.78e-05	7.17e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CD8A—atopic dermatitis	3.78e-05	7.16e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—CXCL8—atopic dermatitis	3.77e-05	7.14e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by EGFR in Cancer—IL6—atopic dermatitis	3.75e-05	7.1e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by PDGF—IL6—atopic dermatitis	3.73e-05	7.07e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—IFNG—atopic dermatitis	3.73e-05	7.06e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CXCL10—atopic dermatitis	3.73e-05	7.06e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—CD4—atopic dermatitis	3.73e-05	7.06e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL18—atopic dermatitis	3.72e-05	7.06e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—TNF—atopic dermatitis	3.72e-05	7.05e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—NFKBIA—atopic dermatitis	3.7e-05	7.01e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CMA1—atopic dermatitis	3.68e-05	6.97e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCL11—atopic dermatitis	3.68e-05	6.97e-05	CbGpPWpGaD
Ruxolitinib—JAK3—GPCR downstream signaling—IL2—atopic dermatitis	3.68e-05	6.97e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—CCR5—atopic dermatitis	3.67e-05	6.96e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—TLR2—atopic dermatitis	3.67e-05	6.95e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CD8A—atopic dermatitis	3.67e-05	6.95e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—MAPK8—atopic dermatitis	3.66e-05	6.95e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—TNF—atopic dermatitis	3.66e-05	6.93e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Innate Immune System—IL6—atopic dermatitis	3.65e-05	6.92e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—IFNG—atopic dermatitis	3.64e-05	6.9e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TAC1—atopic dermatitis	3.63e-05	6.89e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NPS—atopic dermatitis	3.63e-05	6.89e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—IL1B—atopic dermatitis	3.63e-05	6.88e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—CD4—atopic dermatitis	3.63e-05	6.88e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—CD4—atopic dermatitis	3.62e-05	6.85e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—IL2—atopic dermatitis	3.62e-05	6.85e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL18—atopic dermatitis	3.61e-05	6.84e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—IL2—atopic dermatitis	3.6e-05	6.82e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—CD4—atopic dermatitis	3.6e-05	6.82e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Cytokine Signaling in Immune system—IL6—atopic dermatitis	3.59e-05	6.81e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—CXCL10—atopic dermatitis	3.59e-05	6.8e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CXCR3—atopic dermatitis	3.56e-05	6.75e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CD8A—atopic dermatitis	3.56e-05	6.74e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling by NGF—IL6—atopic dermatitis	3.53e-05	6.69e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NPS—atopic dermatitis	3.53e-05	6.69e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TAC1—atopic dermatitis	3.53e-05	6.69e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—CD4—atopic dermatitis	3.52e-05	6.66e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—NGF—atopic dermatitis	3.51e-05	6.65e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—CD4—atopic dermatitis	3.51e-05	6.65e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—CXCL8—atopic dermatitis	3.49e-05	6.62e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Cytokine Signaling in Immune system—IL6—atopic dermatitis	3.49e-05	6.61e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—CASP8—atopic dermatitis	3.47e-05	6.59e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—STAT6—atopic dermatitis	3.46e-05	6.56e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CXCR3—atopic dermatitis	3.46e-05	6.56e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CD79A—atopic dermatitis	3.45e-05	6.54e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IFNG—atopic dermatitis	3.43e-05	6.51e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—NFKBIA—atopic dermatitis	3.43e-05	6.5e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by NGF—IL6—atopic dermatitis	3.43e-05	6.5e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NPS—atopic dermatitis	3.42e-05	6.48e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TAC1—atopic dermatitis	3.42e-05	6.48e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CCR5—atopic dermatitis	3.41e-05	6.47e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—CCL5—atopic dermatitis	3.4e-05	6.45e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Cytokine Signaling in Immune system—IL6—atopic dermatitis	3.38e-05	6.41e-05	CbGpPWpGaD
Ruxolitinib—JAK2—NGF signalling via TRKA from the plasma membrane—IL6—atopic dermatitis	3.38e-05	6.4e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL5—atopic dermatitis	3.38e-05	6.4e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—CD4—atopic dermatitis	3.37e-05	6.38e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CXCR3—atopic dermatitis	3.36e-05	6.36e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Disease—IL6—atopic dermatitis	3.34e-05	6.33e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—IL2—atopic dermatitis	3.34e-05	6.33e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—CASP8—atopic dermatitis	3.34e-05	6.33e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—MAPK8—atopic dermatitis	3.33e-05	6.31e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—IL1B—atopic dermatitis	3.32e-05	6.3e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—CD4—atopic dermatitis	3.32e-05	6.29e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—MAPK8—atopic dermatitis	3.31e-05	6.28e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—IL2—atopic dermatitis	3.31e-05	6.28e-05	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—CXCL8—atopic dermatitis	3.31e-05	6.27e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL5—atopic dermatitis	3.28e-05	6.22e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—atopic dermatitis	3.26e-05	6.19e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CCL5—atopic dermatitis	3.26e-05	6.18e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—CXCL8—atopic dermatitis	3.26e-05	6.17e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—IL1B—atopic dermatitis	3.25e-05	6.15e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—IL2—atopic dermatitis	3.23e-05	6.13e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CCL5—atopic dermatitis	3.21e-05	6.08e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL5—atopic dermatitis	3.18e-05	6.03e-05	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—IL2—atopic dermatitis	3.16e-05	6e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—MAPK8—atopic dermatitis	3.15e-05	5.98e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—IL2—atopic dermatitis	3.11e-05	5.9e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Axon guidance—IL6—atopic dermatitis	3.1e-05	5.88e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CCR5—atopic dermatitis	3.1e-05	5.87e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—CCL5—atopic dermatitis	3.09e-05	5.85e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—CCR5—atopic dermatitis	3.06e-05	5.81e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IL1B—atopic dermatitis	3.06e-05	5.81e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—MAPK8—atopic dermatitis	3.06e-05	5.8e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IL2—atopic dermatitis	3.05e-05	5.78e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—MAPK8—atopic dermatitis	3.05e-05	5.78e-05	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—IL6—atopic dermatitis	3.02e-05	5.73e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NGF—atopic dermatitis	3.02e-05	5.72e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—CXCL8—atopic dermatitis	3.01e-05	5.7e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—IL6—atopic dermatitis	3e-05	5.69e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCR3—atopic dermatitis	3e-05	5.69e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—MAPK8—atopic dermatitis	2.98e-05	5.64e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—MAPK8—atopic dermatitis	2.97e-05	5.63e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NGF—atopic dermatitis	2.97e-05	5.63e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—CXCL8—atopic dermatitis	2.96e-05	5.6e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IFNG—atopic dermatitis	2.95e-05	5.6e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—IL6—atopic dermatitis	2.95e-05	5.59e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CCR5—atopic dermatitis	2.94e-05	5.57e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—NFKBIA—atopic dermatitis	2.93e-05	5.55e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—NFKBIA—atopic dermatitis	2.89e-05	5.49e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CCR5—atopic dermatitis	2.89e-05	5.48e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CXCL10—atopic dermatitis	2.88e-05	5.46e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—IL2—atopic dermatitis	2.87e-05	5.45e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—CD4—atopic dermatitis	2.85e-05	5.41e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—NFKBIA—atopic dermatitis	2.84e-05	5.39e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—IL2—atopic dermatitis	2.83e-05	5.36e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL18—atopic dermatitis	2.82e-05	5.35e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—MAPK8—atopic dermatitis	2.81e-05	5.32e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—IL2—atopic dermatitis	2.8e-05	5.31e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CXCL10—atopic dermatitis	2.8e-05	5.3e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—CCR5—atopic dermatitis	2.78e-05	5.27e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CD8A—atopic dermatitis	2.78e-05	5.27e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—NFKBIA—atopic dermatitis	2.76e-05	5.23e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—TNF—atopic dermatitis	2.74e-05	5.2e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—CD4—atopic dermatitis	2.74e-05	5.19e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CXCL10—atopic dermatitis	2.71e-05	5.14e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NPS—atopic dermatitis	2.67e-05	5.07e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TAC1—atopic dermatitis	2.67e-05	5.07e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—IL6—atopic dermatitis	2.65e-05	5.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—IL6—atopic dermatitis	2.64e-05	5.01e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CASP8—atopic dermatitis	2.64e-05	5.01e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL1B—atopic dermatitis	2.63e-05	4.99e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—CD4—atopic dermatitis	2.63e-05	4.99e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL2—atopic dermatitis	2.63e-05	4.98e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CXCR3—atopic dermatitis	2.62e-05	4.97e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—IL6—atopic dermatitis	2.6e-05	4.93e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CASP8—atopic dermatitis	2.56e-05	4.86e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NFKBIA—atopic dermatitis	2.49e-05	4.72e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—IL6—atopic dermatitis	2.49e-05	4.72e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CASP8—atopic dermatitis	2.49e-05	4.72e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL5—atopic dermatitis	2.49e-05	4.71e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCL5—atopic dermatitis	2.48e-05	4.7e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NFKBIA—atopic dermatitis	2.45e-05	4.64e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—CXCL8—atopic dermatitis	2.45e-05	4.64e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—MAPK8—atopic dermatitis	2.42e-05	4.58e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCL5—atopic dermatitis	2.41e-05	4.56e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—IL6—atopic dermatitis	2.35e-05	4.46e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CCR5—atopic dermatitis	2.35e-05	4.45e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—IL6—atopic dermatitis	2.34e-05	4.44e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IL2—atopic dermatitis	2.34e-05	4.43e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCL5—atopic dermatitis	2.33e-05	4.42e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—IL6—atopic dermatitis	2.33e-05	4.41e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—MAPK8—atopic dermatitis	2.32e-05	4.4e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NGF—atopic dermatitis	2.3e-05	4.35e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IFNG—atopic dermatitis	2.25e-05	4.26e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCR5—atopic dermatitis	2.23e-05	4.23e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NGF—atopic dermatitis	2.23e-05	4.23e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—CXCL8—atopic dermatitis	2.22e-05	4.21e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—IL6—atopic dermatitis	2.21e-05	4.2e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IFNG—atopic dermatitis	2.18e-05	4.13e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CD4—atopic dermatitis	2.17e-05	4.11e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCR5—atopic dermatitis	2.17e-05	4.11e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NGF—atopic dermatitis	2.16e-05	4.1e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—NFKBIA—atopic dermatitis	2.15e-05	4.08e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—MAPK8—atopic dermatitis	2.15e-05	4.08e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—IL6—atopic dermatitis	2.13e-05	4.03e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL2—atopic dermatitis	2.12e-05	4.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CXCL10—atopic dermatitis	2.12e-05	4.02e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—IL6—atopic dermatitis	2.12e-05	4.01e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IFNG—atopic dermatitis	2.12e-05	4.01e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CD4—atopic dermatitis	2.11e-05	3.99e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCR5—atopic dermatitis	2.1e-05	3.99e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—TNF—atopic dermatitis	2.08e-05	3.94e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CXCL8—atopic dermatitis	2.06e-05	3.91e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CD4—atopic dermatitis	2.04e-05	3.87e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—IL6—atopic dermatitis	2.01e-05	3.82e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL1B—atopic dermatitis	2e-05	3.8e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL2—atopic dermatitis	2e-05	3.78e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL2—atopic dermatitis	1.97e-05	3.74e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—IL6—atopic dermatitis	1.96e-05	3.72e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—IL6—atopic dermatitis	1.96e-05	3.72e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—IL6—atopic dermatitis	1.96e-05	3.71e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—IL6—atopic dermatitis	1.95e-05	3.69e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL1B—atopic dermatitis	1.95e-05	3.69e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CD4—atopic dermatitis	1.94e-05	3.69e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CASP8—atopic dermatitis	1.94e-05	3.68e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL2—atopic dermatitis	1.94e-05	3.67e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—IL6—atopic dermatitis	1.9e-05	3.6e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—IL6—atopic dermatitis	1.9e-05	3.6e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NFKBIA—atopic dermatitis	1.89e-05	3.59e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL1B—atopic dermatitis	1.89e-05	3.58e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL2—atopic dermatitis	1.88e-05	3.56e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—CXCL8—atopic dermatitis	1.85e-05	3.51e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NFKBIA—atopic dermatitis	1.84e-05	3.48e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—MAPK8—atopic dermatitis	1.84e-05	3.48e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCL5—atopic dermatitis	1.82e-05	3.46e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MAPK8—atopic dermatitis	1.82e-05	3.44e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IL6—atopic dermatitis	1.79e-05	3.4e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—MAPK8—atopic dermatitis	1.78e-05	3.38e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NFKBIA—atopic dermatitis	1.78e-05	3.38e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CXCL8—atopic dermatitis	1.78e-05	3.37e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—IL2—atopic dermatitis	1.77e-05	3.35e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CXCL8—atopic dermatitis	1.75e-05	3.31e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—MAPK8—atopic dermatitis	1.73e-05	3.28e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL2—atopic dermatitis	1.7e-05	3.22e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NGF—atopic dermatitis	1.69e-05	3.2e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—IL6—atopic dermatitis	1.69e-05	3.2e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—CXCL8—atopic dermatitis	1.68e-05	3.19e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—IL6—atopic dermatitis	1.68e-05	3.18e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL2—atopic dermatitis	1.67e-05	3.16e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—IL6—atopic dermatitis	1.66e-05	3.15e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IFNG—atopic dermatitis	1.65e-05	3.13e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCR5—atopic dermatitis	1.64e-05	3.11e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GLB1—atopic dermatitis	1.64e-05	3.11e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL2—atopic dermatitis	1.61e-05	3.05e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CD4—atopic dermatitis	1.6e-05	3.03e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ADSL—atopic dermatitis	1.57e-05	2.98e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MAPK8—atopic dermatitis	1.56e-05	2.96e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL6—atopic dermatitis	1.54e-05	2.92e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MAPK8—atopic dermatitis	1.54e-05	2.91e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—IL6—atopic dermatitis	1.48e-05	2.81e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL1B—atopic dermatitis	1.47e-05	2.79e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CD4—atopic dermatitis	1.47e-05	2.79e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL2—atopic dermatitis	1.47e-05	2.78e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—IL6—atopic dermatitis	1.42e-05	2.7e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NFKBIA—atopic dermatitis	1.39e-05	2.64e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IL6—atopic dermatitis	1.37e-05	2.6e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MAPK8—atopic dermatitis	1.35e-05	2.56e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CXCL8—atopic dermatitis	1.35e-05	2.56e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CXCL8—atopic dermatitis	1.31e-05	2.48e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL2—atopic dermatitis	1.29e-05	2.45e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CXCL8—atopic dermatitis	1.27e-05	2.41e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL2—atopic dermatitis	1.25e-05	2.37e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL6—atopic dermatitis	1.25e-05	2.36e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL2—atopic dermatitis	1.22e-05	2.3e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MAPK8—atopic dermatitis	1.19e-05	2.25e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL6—atopic dermatitis	1.17e-05	2.22e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL6—atopic dermatitis	1.16e-05	2.2e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MAPK8—atopic dermatitis	1.15e-05	2.19e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL6—atopic dermatitis	1.14e-05	2.16e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MAPK8—atopic dermatitis	1.12e-05	2.12e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL6—atopic dermatitis	1.1e-05	2.09e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—IL6—atopic dermatitis	1.05e-05	1.99e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL6—atopic dermatitis	9.98e-06	1.89e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CXCL8—atopic dermatitis	9.94e-06	1.88e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL6—atopic dermatitis	9.81e-06	1.86e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL2—atopic dermatitis	9.5e-06	1.8e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL6—atopic dermatitis	9.45e-06	1.79e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MAPK8—atopic dermatitis	8.74e-06	1.66e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL6—atopic dermatitis	8.63e-06	1.64e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—IL6—atopic dermatitis	7.97e-06	1.51e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL6—atopic dermatitis	7.59e-06	1.44e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL6—atopic dermatitis	7.36e-06	1.4e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL6—atopic dermatitis	7.14e-06	1.35e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL6—atopic dermatitis	5.58e-06	1.06e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPARA—atopic dermatitis	5.33e-06	1.01e-05	CbGpPWpGaD
